Skip to Content
Merck
  • Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1.

The Journal of biological chemistry (2005-03-18)
Richard I Feldman, James M Wu, Mark A Polokoff, Monica J Kochanny, Harald Dinter, Daguang Zhu, Sandra L Biroc, Bruno Alicke, Judi Bryant, Shendong Yuan, Brad O Buckman, Dao Lentz, Mike Ferrer, Marc Whitlow, Marc Adler, Silke Finster, Zheng Chang, Damian O Arnaiz
ABSTRACT

The phosphoinositide 3-kinase/3-phosphoinositide-dependent kinase 1 (PDK1)/Akt signaling pathway plays a key role in cancer cell growth, survival, and tumor angiogenesis and represents a promising target for anticancer drugs. Here, we describe three potent PDK1 inhibitors, BX-795, BX-912, and BX-320 (IC(50) = 11-30 nm) and their initial biological characterization. The inhibitors blocked PDK1/Akt signaling in tumor cells and inhibited the anchorage-dependent growth of a variety of tumor cell lines in culture or induced apoptosis. A number of cancer cell lines with elevated Akt activity were >30-fold more sensitive to growth inhibition by PDK1 inhibitors in soft agar than on tissue culture plastic, consistent with the cell survival function of the PDK1/Akt signaling pathway, which is particularly important for unattached cells. BX-320 inhibited the growth of LOX melanoma tumors in the lungs of nude mice after injection of tumor cells into the tail vein. The effect of BX-320 on cancer cell growth in vitro and in vivo indicates that PDK1 inhibitors may have clinical utility as anticancer agents.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
BX-795 hydrochloride, ≥98% (HPLC)
Pricing and availability is not currently available.